Based on these results, the FDA approved this drug for a similar indication ... decision marks the second EC approval for Pfizer this year in the hemophilia space. Earlier in July, the FDA ...
Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has approved HYMPAVZI™ (marstacimab-hncq) for routine ...
Pfizer’s Mylotarg is back ... after the FDA reapproved it in the aggressive blood cancer, acute myeloid leukaemia. The world’s first approved antibody-drug conjugate, where a targeted antibody ...
Centessa had recently conducted an interim analysis of a phase 2 study of its drug ... regulatory wins for Pfizer. First, the Big Pharma scored an FDA approval for its hemophilia B gene therapy ...
Pfizer has won European Commission approval of its Hympavzi treatment for certain patients with the blood-clotting disorder hemophilia. The New York drugmaker on Wednesday said the approval covers ...
When a room of physicians at ASH 2024 was asked whether they had prescribed a gene therapy in a commercial context, only a ...
Based on these results, the FDA approved this drug for a similar indication last month ... The latest decision marks the second EC approval for Pfizer this year in the hemophilia space. Earlier in ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback